Bayer Aktienges Ads (BAYRY) 128.7400 $BAYRY
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Global Acaricides Market - Forecasts to 2019
M2 - Thu Jul 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdkmx2/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. Chemicals that are used to kill ticks and mites are known as acaricides. They help in increasing productivity by keeping animals and crops healthy and disease-free. Cattle, when treated with acaricides are less susceptible to tick-borne diseases and there is an increase in the milk and other product yield. The acaricides market is growing steadily due to increase in the demand of the crops and animal products. Factors that act as driving forces for this market are the increase in productivity, development in the crop protection industry, and the growing demand of crops and animal products across the world. The high cost of raw materials and the strict regulatory norms imposed by some governments pose as hindrances for this market. Various secondary sources such as encyclopedias, directories, and databases, were used to identify and collect information useful for this extensive market-oriented study of the acaricides market. The primary sources-experts from related industries and suppliers-were interviewed to obtain and verify critical information as well as to assess the future prospects of the global acaricides market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Analysis 5 Market Overview 6 Industry Analysis 7 Acaricides Market, By Type 8 Acaricides Market, By Application 9 Acaricides Market, By Mode of Action 10 Acaricides Market, By Geography 11 Competitive Landscape 12 Company Profile Companies Mentioned: - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/bd...des_market
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
European Stocks Steady as Barclays Reports, AstraZeneca Buys Generic Line
at The Street - Wed Jul 30, 5:31AM CDT
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
Merck (MRK) Tops Q2 Earnings Expectations on Cost Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 11:30AM CDT
Merck's (MRK) second quarter results were better-than-expected even though the company is facing generic competition for quite a few products.
Global Synthetic Biology Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xp9d8/global_synthetic) has announced the addition of the "Global Synthetic Biology Market 2014-2018" report to their offering. The term synthetic biology covers the designing and engineering of completely new biological parts, devices, and organisms as well as the redesigning of natural biological systems that provide improved and desirable functions. It is considered to be a form of extreme genetic engineering because it not only alters existing metabolic pathways, but also creates new ones. The engineered biological systems can be used to manipulate chemicals, fabricate materials and structures, produce energy, provide GM food, improve the efficiency of drugs and vaccines, and maintain a sustainable environment. The analysts forecast the Global Synthetic Biology market will grow at a CAGR of 33.8 percent over the period 2013-2018. The Global Synthetic Biology market can be categorized on the basis of technology into four segments: Genome Engineering. DNA Sequencing, Bioinformatics, and Biological Components and Integrated Systems. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Product 09. Market Segmentation by Applications 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Amyris Inc. - E. I. du Pont de Nemours and Co. - Thermo Fisher Scientific Inc. - Synthetic Genomics Inc. - Algenol Biofuels Inc. - ATG:biosynthetics GmbH - Bayer AG - Bioneer Corp. - Biosearch Technologies Inc. - Bristol-Myers Squibb Co. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - Evolva Holdings SA - Exxon Mobil Corp. - GeneWorks Pty Ltd. - Genomatica Inc. - Gevo Inc. - Ginkgo Bioworks - Green Biologics Ltd. - New England Biolabs Inc. - OriGene Technologies Inc. - REG Life Sciences LLC - Royal DSM - Synthorx Inc. For more information visit http://www.researchandmarkets.com/research/4x..._synthetic
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Bayer Battles New Insecticide Research Affecting 20% of Sales
at The Street - Wed Jul 23, 9:18AM CDT
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.
Global Women's Health Market 2014-2018
M2 - Wed Jul 23, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kxqgp/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering. The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018. Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment: - Postmenopausal Osteoporosis (Drugs) - Hormonal Contraceptives (Drugs and Devices) - Menopause (Drugs) - Infertility (Drugs) - Endometriosis (Drugs) - Polycystic Ovary Syndrome (Drugs) The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Bayer AG - Eli Lilly and Co. - Merck & Co. - Pfizer Inc. According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva. For more information visit http://www.researchandmarkets.com/research/4k...bal_womens
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Animal Antimicrobials and Antibiotics (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides) Market 2014-2018
M2 - Wed Jul 23, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hmcm5/animal) has announced the addition of the "Animal Antimicrobials and Antibiotics Market by Products, Animals & Mode Of Delivery - Global Forecasts to 2018" report to their offering. At present, the global antimicrobials and antibiotics market is driven by the growing need to preserve animal health owing to rising demand for animal proteins across the globe, and growing demand in the companion animals segment. Growing livestock population, increasing incidences of disease outbreaks and increase in the companion animal ownership are some of the factors driving the growth of this market to a certain extent. Besides the structural market drivers, there are strong geographic drivers for the growth of the animal antimicrobials and antibiotics market. Emerging markets are becoming increasingly attractive. The Asian and Latin American region form one of the most promising animal antimicrobials and antibiotics markets in the world. Developing countries such as China and India have a relatively high CAGR rate and are expected to witness significant market growth in the forecast period. The growth in these regions is mainly attributed to the rise in demand for animal protein products, along with an increase in the trend of companion animal ownership in these regions. Today, the animal antimicrobials and antibiotics market showcase a sluggish growth, owing to the regulatory authorities restricting their use, increased usage of in-feed enzymes, competitive exclusion products and probiotics as an alternative to antibiotics and prophylactic use of antibiotics being replaced by good husbandry, environment and hygienic practices. Report Scope Products - Tetracyclines - Penicillins - Sulfonamides - Aminoglycosides Animals - Dog - Poultry - Swine Mode Of Delivery - Premixes - Oral Powders - Solutions - Injections Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Veterinary Antimicrobials And Antibiotics Market, By Product 6 Veterinary Antimicrobials And Antibiotics Market, By Mode Of Delivery 7 Veterinary Antimicrobials And Antibiotics Market, By Type Of Animal 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned - Bayer Ag - Boehringer Ingelheim - Ceva Sante Animale - Eli Lilly And Company - Merck And Co., Inc. - Novartis Ag - Sanofi - Vetoquinol - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4hmcm5/animal
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.
2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global
Global Gynecological Devices Market to 2018: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instrument
M2 - Mon Jul 21, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n4f66s/global) has announced the addition of the "Global Gynecological Devices Market 2014-2018" report to their offering. The Global Gynecological Devices market will grow at a CAGR of 6.63 percent over the period 2014-2018. Gynecological devices have been broadly classified into wide categories based on their operations. These devices are used for the treatment of different gynecological conditions that affect the female reproduction organs, female fertility, menorrhagia (heavy menstrual periods), infections, and disorders such as endometriosis, gestational diabetes, polycystic ovary syndrome, uterine fibroids, and pelvic floor disorders. Every woman faces a gynecological condition at some point in her life. Several conditions may be easily treatable and several may be life threatening. The gynecological devices help by having an impact on a woman's infertility , treat serious illnesses, and treat the devastating consequences that are life threatening. The gynecological devices are made to perform with advanced technologies and procedures to improve the treatment of complex gynecology surgeries. Several devices are portable, disposable, and very easy to handle and can be used in any gynecology centers. This report covers the present scenario and the growth prospects of the Global Gynecological Devices market for the period 2014-2018. The Global Gynecological Devices market can be segmented into four divisions: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instruments. These are sets of methodologies and technologies that transform unstructured and structured data into meaningful and useful information processes. The report, the Global Gynecological Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bayer AG - Boston Scientific Corp. - CooperSurgical Inc. - Ethicon Inc. - Hologic Inc. - Medtronic Inc. - Olympus Corp. - Stryker Corp. Other Prominent Vendors - ATMOS MedizinTechnik GmbH & Co. KG - BTL Medical technologies Inc. - KARL STORZ GmbH & Co. KG - Meditelle Medical Equipment Ltd. - Richard Wolf GmbH - Welch Allyn, Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/n4f66s/global
New Study Touts Benefits of Organic Goods, Questions Pesticides and GMOs
Brian Stoffel, The Motley Fool - Motley Fool - Sat Jul 19, 9:24AM CDT
Scientists estimate that we humans—since our earliest ancestors—have been running around the earth for well over two million years. Only within the past century—or 0.005% of that time—have we come to rely so heavily on the use of pesticides to help...
Research and Markets: Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
Business Wire - Thu Jul 17, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global
Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.
Global Acaricides Market - Forecasts to 2019
M2 - Thu Jul 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdkmx2/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. Chemicals that are used to kill ticks and mites are known as acaricides. They help in increasing productivity by keeping animals and crops healthy and disease-free. Cattle, when treated with acaricides are less susceptible to tick-borne diseases and there is an increase in the milk and other product yield. The acaricides market is growing steadily due to increase in the demand of the crops and animal products. Factors that act as driving forces for this market are the increase in productivity, development in the crop protection industry, and the growing demand of crops and animal products across the world. The high cost of raw materials and the strict regulatory norms imposed by some governments pose as hindrances for this market. Various secondary sources such as encyclopedias, directories, and databases, were used to identify and collect information useful for this extensive market-oriented study of the acaricides market. The primary sources-experts from related industries and suppliers-were interviewed to obtain and verify critical information as well as to assess the future prospects of the global acaricides market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Analysis 5 Market Overview 6 Industry Analysis 7 Acaricides Market, By Type 8 Acaricides Market, By Application 9 Acaricides Market, By Mode of Action 10 Acaricides Market, By Geography 11 Competitive Landscape 12 Company Profile Companies Mentioned: - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/bd...des_market
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.
Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
European Stocks Steady as Barclays Reports, AstraZeneca Buys Generic Line
at The Street - Wed Jul 30, 5:31AM CDT
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.
Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...
Merck (MRK) Tops Q2 Earnings Expectations on Cost Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 11:30AM CDT
Merck's (MRK) second quarter results were better-than-expected even though the company is facing generic competition for quite a few products.
Global Synthetic Biology Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xp9d8/global_synthetic) has announced the addition of the "Global Synthetic Biology Market 2014-2018" report to their offering. The term synthetic biology covers the designing and engineering of completely new biological parts, devices, and organisms as well as the redesigning of natural biological systems that provide improved and desirable functions. It is considered to be a form of extreme genetic engineering because it not only alters existing metabolic pathways, but also creates new ones. The engineered biological systems can be used to manipulate chemicals, fabricate materials and structures, produce energy, provide GM food, improve the efficiency of drugs and vaccines, and maintain a sustainable environment. The analysts forecast the Global Synthetic Biology market will grow at a CAGR of 33.8 percent over the period 2013-2018. The Global Synthetic Biology market can be categorized on the basis of technology into four segments: Genome Engineering. DNA Sequencing, Bioinformatics, and Biological Components and Integrated Systems. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Product 09. Market Segmentation by Applications 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Amyris Inc. - E. I. du Pont de Nemours and Co. - Thermo Fisher Scientific Inc. - Synthetic Genomics Inc. - Algenol Biofuels Inc. - ATG:biosynthetics GmbH - Bayer AG - Bioneer Corp. - Biosearch Technologies Inc. - Bristol-Myers Squibb Co. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - Evolva Holdings SA - Exxon Mobil Corp. - GeneWorks Pty Ltd. - Genomatica Inc. - Gevo Inc. - Ginkgo Bioworks - Green Biologics Ltd. - New England Biolabs Inc. - OriGene Technologies Inc. - REG Life Sciences LLC - Royal DSM - Synthorx Inc. For more information visit http://www.researchandmarkets.com/research/4x..._synthetic
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Bayer Battles New Insecticide Research Affecting 20% of Sales
at The Street - Wed Jul 23, 9:18AM CDT
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.
Global Women's Health Market 2014-2018
M2 - Wed Jul 23, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kxqgp/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering. The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018. Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment: - Postmenopausal Osteoporosis (Drugs) - Hormonal Contraceptives (Drugs and Devices) - Menopause (Drugs) - Infertility (Drugs) - Endometriosis (Drugs) - Polycystic Ovary Syndrome (Drugs) The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Bayer AG - Eli Lilly and Co. - Merck & Co. - Pfizer Inc. According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva. For more information visit http://www.researchandmarkets.com/research/4k...bal_womens
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Global Animal Antimicrobials and Antibiotics (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides) Market 2014-2018
M2 - Wed Jul 23, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hmcm5/animal) has announced the addition of the "Animal Antimicrobials and Antibiotics Market by Products, Animals & Mode Of Delivery - Global Forecasts to 2018" report to their offering. At present, the global antimicrobials and antibiotics market is driven by the growing need to preserve animal health owing to rising demand for animal proteins across the globe, and growing demand in the companion animals segment. Growing livestock population, increasing incidences of disease outbreaks and increase in the companion animal ownership are some of the factors driving the growth of this market to a certain extent. Besides the structural market drivers, there are strong geographic drivers for the growth of the animal antimicrobials and antibiotics market. Emerging markets are becoming increasingly attractive. The Asian and Latin American region form one of the most promising animal antimicrobials and antibiotics markets in the world. Developing countries such as China and India have a relatively high CAGR rate and are expected to witness significant market growth in the forecast period. The growth in these regions is mainly attributed to the rise in demand for animal protein products, along with an increase in the trend of companion animal ownership in these regions. Today, the animal antimicrobials and antibiotics market showcase a sluggish growth, owing to the regulatory authorities restricting their use, increased usage of in-feed enzymes, competitive exclusion products and probiotics as an alternative to antibiotics and prophylactic use of antibiotics being replaced by good husbandry, environment and hygienic practices. Report Scope Products - Tetracyclines - Penicillins - Sulfonamides - Aminoglycosides Animals - Dog - Poultry - Swine Mode Of Delivery - Premixes - Oral Powders - Solutions - Injections Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Veterinary Antimicrobials And Antibiotics Market, By Product 6 Veterinary Antimicrobials And Antibiotics Market, By Mode Of Delivery 7 Veterinary Antimicrobials And Antibiotics Market, By Type Of Animal 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned - Bayer Ag - Boehringer Ingelheim - Ceva Sante Animale - Eli Lilly And Company - Merck And Co., Inc. - Novartis Ag - Sanofi - Vetoquinol - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4hmcm5/animal
Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.
2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global
Global Gynecological Devices Market to 2018: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instrument
M2 - Mon Jul 21, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n4f66s/global) has announced the addition of the "Global Gynecological Devices Market 2014-2018" report to their offering. The Global Gynecological Devices market will grow at a CAGR of 6.63 percent over the period 2014-2018. Gynecological devices have been broadly classified into wide categories based on their operations. These devices are used for the treatment of different gynecological conditions that affect the female reproduction organs, female fertility, menorrhagia (heavy menstrual periods), infections, and disorders such as endometriosis, gestational diabetes, polycystic ovary syndrome, uterine fibroids, and pelvic floor disorders. Every woman faces a gynecological condition at some point in her life. Several conditions may be easily treatable and several may be life threatening. The gynecological devices help by having an impact on a woman's infertility , treat serious illnesses, and treat the devastating consequences that are life threatening. The gynecological devices are made to perform with advanced technologies and procedures to improve the treatment of complex gynecology surgeries. Several devices are portable, disposable, and very easy to handle and can be used in any gynecology centers. This report covers the present scenario and the growth prospects of the Global Gynecological Devices market for the period 2014-2018. The Global Gynecological Devices market can be segmented into four divisions: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instruments. These are sets of methodologies and technologies that transform unstructured and structured data into meaningful and useful information processes. The report, the Global Gynecological Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bayer AG - Boston Scientific Corp. - CooperSurgical Inc. - Ethicon Inc. - Hologic Inc. - Medtronic Inc. - Olympus Corp. - Stryker Corp. Other Prominent Vendors - ATMOS MedizinTechnik GmbH & Co. KG - BTL Medical technologies Inc. - KARL STORZ GmbH & Co. KG - Meditelle Medical Equipment Ltd. - Richard Wolf GmbH - Welch Allyn, Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/n4f66s/global
New Study Touts Benefits of Organic Goods, Questions Pesticides and GMOs
Brian Stoffel, The Motley Fool - Motley Fool - Sat Jul 19, 9:24AM CDT
Scientists estimate that we humans—since our earliest ancestors—have been running around the earth for well over two million years. Only within the past century—or 0.005% of that time—have we come to rely so heavily on the use of pesticides to help...
Research and Markets: Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
Business Wire - Thu Jul 17, 1:06PM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering.
Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global
